Emotional Brain’s personalized medicine approach has led to proprietary drug combinations, companion diagnostic devices and medication administration technologies.
An extensive patent portfolio has been developed protecting Emotional Brain’s innovative technology in the United States, Europe, and in other commercial relevant markets. This portfolio includes over 60 issued patents and at least 50 pending applications, based on eight different patent families.
In addition to protecting our proprietary drug combinations, patents have also been granted on our dual-route/dual-release administration technology that combines two routes of administration and two release profiles in a single, convenient tablet. Patent applications have also been filed on our internally developed companion diagnostic device, which is able to accurately predict drug responders from drug non-responders, as well as our enabling manufacturing process for producing our dual-route/dual-release tablets.